Regeneron Pharmaceuticals Inc (REGN)
782.51
-21.82
(-2.71%)
USD |
NASDAQ |
Nov 14, 16:00
780.00
-2.51
(-0.32%)
After-Hours: 20:00
Regeneron Pharmaceuticals Free Cash Flow (Quarterly): 1.049B for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.049B |
| June 30, 2024 | 143.10M |
| March 31, 2024 | 1.351B |
| December 31, 2023 | 776.20M |
| September 30, 2023 | 914.40M |
| June 30, 2023 | 888.50M |
| March 31, 2023 | 1.088B |
| December 31, 2022 | 1.468B |
| September 30, 2022 | -440.40M |
| June 30, 2022 | 410.80M |
| March 31, 2022 | 1.960B |
| December 31, 2021 | 2.218B |
| September 30, 2021 | 3.280B |
| June 30, 2021 | 478.20M |
| March 31, 2021 | 553.20M |
| December 31, 2020 | 1.070B |
| September 30, 2020 | -407.50M |
| June 30, 2020 | 813.50M |
| March 31, 2020 | 527.90M |
| December 31, 2019 | 648.40M |
| September 30, 2019 | 435.60M |
| June 30, 2019 | 93.70M |
| March 31, 2019 | 822.70M |
| December 31, 2018 | 643.30M |
| September 30, 2018 | 346.70M |
| Date | Value |
|---|---|
| June 30, 2018 | 282.60M |
| March 31, 2018 | 539.40M |
| December 31, 2017 | 459.30M |
| September 30, 2017 | 355.18M |
| June 30, 2017 | -85.42M |
| March 31, 2017 | 305.44M |
| December 31, 2016 | 239.97M |
| September 30, 2016 | 532.47M |
| June 30, 2016 | 260.66M |
| March 31, 2016 | -59.10M |
| December 31, 2015 | 104.04M |
| September 30, 2015 | 746.75M |
| June 30, 2015 | 17.94M |
| March 31, 2015 | -215.89M |
| December 31, 2014 | 80.63M |
| September 30, 2014 | 84.55M |
| June 30, 2014 | 265.54M |
| March 31, 2014 | -11.30M |
| December 31, 2013 | 212.75M |
| September 30, 2013 | 60.76M |
| June 30, 2013 | 93.71M |
| March 31, 2013 | 65.04M |
| December 31, 2012 | 78.02M |
| September 30, 2012 | -12.63M |
| June 30, 2012 | -91.25M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-440.40M
Minimum
Sep 2022
3.280B
Maximum
Sep 2021
939.50M
Average
851.00M
Median
Free Cash Flow (Quarterly) Benchmarks
| Amgen Inc | 3.314B |
| Eli Lilly and Co | -458.90M |
| Pfizer Inc | 6.063B |
| AbbVie Inc | 5.198B |
| Biogen Inc | 805.60M |